Dapagliflozin/Bisoprolol fumarate

Asset

Combines SGLT2 inhibition and beta-1 adrenergic blockade to treat heart failure.

Stage
Phase 3
Modality
Small molecule
Target
Not known
1
Indication
1
Trial
1
Developer

Trial CTIS2026-526510-90-00 is still running. Trial CTIS2026-526510-90-00 updated in its registry on Nov 13, 2026. euclinicaltrials.eu

Indications

1

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors12
  • Signals3

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets